A fixed dose combination of nivolumab and relatlimab is in development for the treatment of advanced and metastatic melanoma patients that have not received previous treatment. Melanoma is a cancer of the skin, when is advanced or metastatic, the cancer has spread to other organs and tissues such as lymph nodes and the brain. Metastatic melanoma can present a range of different symptoms including lumps under the skin, swollen lymph nodes, bone pain and headaches. At this stage the cancer can’t be cured.
Nivolumab works by improving the activity of white blood cells increasing the ability of the immune system to kill cancer cells. Relatlimab has the potential to increase the immune system response and kill cancer cells. If licenced for this indication, a fixed dose combination of intravenous nivolumab and relatlimab may provide a new therapeutic option for untreated patients that shows similar adverse effects than treatment with nivolumab alone.
Nivolumab in combination with ipilimumab is in clinical development for PD-L1 positive patients with previously untreated unresectable or metastatic urothelial cancer regardless of cisplatin eligibility. Urothelial cancer, a subset of bladder cancer, occurs on the lining of the renal pelvis, ureter, bladder and urethra, and other parts of the urinary system. In some cases,the tumour spreads into the surrounding muscles or other parts of the body which means that it cannot be cured by surgery. Metastatic urothelial cancer occurs when the cancer has spread to other parts of the body, such as the liver or bones. The symptom of urothelial cancer is blood in the urine, but symptoms may only appear once the cancer grows larger or into the deeper layers of the bladder wall for both men and women. Other symptoms may include increased frequency/urgency/pain of urine passing, weight loss, back/lower tummy/bone pain, fatigue and illness.